TaiwanJ Pharmaceuticals Co (ROCO:6549) Debt-to-Equity : 0.02 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is TaiwanJ Pharmaceuticals Co Debt-to-Equity?

TaiwanJ Pharmaceuticals Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$0.70 Mil. TaiwanJ Pharmaceuticals Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$0.47 Mil. TaiwanJ Pharmaceuticals Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$66.94 Mil. TaiwanJ Pharmaceuticals Co's debt to equity for the quarter that ended in Dec. 2023 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for TaiwanJ Pharmaceuticals Co's Debt-to-Equity or its related term are showing as below:

ROCO:6549' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.03
Current: 0.02

During the past 11 years, the highest Debt-to-Equity Ratio of TaiwanJ Pharmaceuticals Co was 0.03. The lowest was 0.00. And the median was 0.01.

ROCO:6549's Debt-to-Equity is ranked better than
87.8% of 1066 companies
in the Biotechnology industry
Industry Median: 0.145 vs ROCO:6549: 0.02

TaiwanJ Pharmaceuticals Co Debt-to-Equity Historical Data

The historical data trend for TaiwanJ Pharmaceuticals Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiwanJ Pharmaceuticals Co Debt-to-Equity Chart

TaiwanJ Pharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.03

0.02

TaiwanJ Pharmaceuticals Co Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-	-	0.03	0.02	0.02

Competitive Comparison of TaiwanJ Pharmaceuticals Co's Debt-to-Equity

For the Biotechnology subindustry, TaiwanJ Pharmaceuticals Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TaiwanJ Pharmaceuticals Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiwanJ Pharmaceuticals Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where TaiwanJ Pharmaceuticals Co's Debt-to-Equity falls into.

TaiwanJ Pharmaceuticals Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

TaiwanJ Pharmaceuticals Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.699	+	0.472)	/	66.94
	=	0.02

TaiwanJ Pharmaceuticals Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.699	+	0.472)	/	66.94
	=	0.02

TaiwanJ Pharmaceuticals Co (ROCO:6549) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

TaiwanJ Pharmaceuticals Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of TaiwanJ Pharmaceuticals Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

TaiwanJ Pharmaceuticals Co (ROCO:6549) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiwanJ Pharmaceuticals Co Ltd (ROCO:6549) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Rm. D207, Number 2, Sec.2, ShengYi Road, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei, TWN, 30261

Website

http://www.taiwanj.com

TaiwanJ Pharmaceuticals Co Ltd is a Taiwan based specialty pharmaceutical company focused on small molecules for unmet medical needs like chronic organ inflammation of metabolic, autoimmune and infectious etiologies. It is also involved in developing novel chemical entities (NCEs) for chronic liver diseases and allergy/asthma.

TaiwanJ Pharmaceuticals Co (ROCO:6549) Headlines

No Headlines